Directorio
We are doing this study to find out if an investigational drug called TP-3654 (the study drug) is a safe and effective treatment for myelofibrosis. The study drug will be tested at different doses to find out what effects, if any, it has on myelofibrosis.
We are doing this study to find out if an experimental drug called BGB-43395 (the study drug) is a safe and effective option for people with for breast cancer and other advanced solid tumors. We want to know how the study drug works on its own and in combination with other cancer drugs.
We are doing this study to find the most safe and effective long-term dose of an experimental drug called zanubrutinib (the study drug) when it is given alone or in combination with other cancer drugs. We want to know how well this study drug works in people with B-cell cancers who are currently participating or previously participated in a BeiGene-sponsored study.
The study has 4 parts: screening, taking the study drug, stopping the drug, and follow-up. You’ll get tests like blood work, heart checks, and scans. You’ll be randomly given one of two medicines: BGB-16673 or Pirtobrutinib, both taken once a day. After stopping the medicine, you’ll return for a check-up in about a month. If your cancer hasn’t gotten worse, you’ll visit every 6 months. If it has, the study team will check on you by phone or email. The whole study may last about 3 years with around 13 visits.
We are doing this study to find the most effective, safe dose of an experimental drug called ficerafusp alfa (BCA101 - the study drug) when it is given in combination with pembrolizumab for people who have metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
We are doing this study to collect data, liquid biopsies (blood and urine), and cancer specimens from women with primary epithelial ovarian, peritoneal, or tubal cancer. We are using this information and these samples to create a biobank that might identify future therapeutic targets and help develop new therapies for these types of cancer.
We are doing this study to find the most effective, safe dose of an experimental drug called BHV-1530 (the study drug) for adults who have advanced or metastatic solid tumors.